YES :)
Wednesday April 5, 11:23 am Eastern Time
Company Press Release
Sanguine Corp. Announces an Agreement, Which Signs Professor L. Cass Terry, M.D., Ph.D., and Pharm.D. As the Chief of Medical Advisory Board and as a Member of the Board of Directors
PASADENA, Calif.--(BUSINESS WIRE)--April 5, 2000--Sanguine Corp. (OTC BB: SGNC - news) Wednesday announced an agreement, which signs Professor L. Cass Terry, M.D., Ph.D., Pharm.D. as the chief of medical advisory board and as a member of the board of directors.
Dr. Terry, reporting directly to Admiral Van Orden, will work with the medical team to direct efforts in microcirculation and the effects of PHER-02 in the brain.
Terry is chairman of the department of neurology and professor of neurology and physiology at Medical College of Wisconsin; he is former chief of staff at Froedtert Memorial Hospital and associate dean for ambulatory care at the Medical College.
Terry has done extensive neuroscience research in brain aging mechanisms, memory impairment and its prevention, neurotransmitters, neuroendocrine mechanisms and the blood brain barrier. He has been instrumental in developing stroke and head injury programs and conducts clinical trials in these areas.
His knowledge and experience will be crucial in evaluating products, procedures, and patents where microcirculation is of issue.
Because PHER-O21 is 1/900th the size of a human red blood cell, its ability to circumnavigate obstructions or further penetrate small vessels and provide oxygen to ischemic tissue within the brain has tremendous potential in the treatment of both thrombotic and embolic stroke victims, acute head injury, Alzheimer's disease, multi-infact disease, and vasospasm resulting from subarachnoid hemorrhage.
As Chief of the Medical Advisory Board, Terry will be instrumental toward the success of PHER-O2 in microcirculatory applications beyond the original primary focuses of cardioplegia, stroke, heart attacks, transfusions and other surgical applications.
Notice: This news release contains, and oral statements made from time to time by company representatives concerning the information contained herein may contain so-called ``forward-looking statements.'
These statements can be identified with introductory words such as ``expects,' ``plans,' ``will,' ``estimates,' ``forecasts,' ``projects' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing the company's growth strategy, operating and financial goals, regulatory submissions and approvals and development programs.
Many factors may cause actual results to differ from the company's forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
--------------------------------------------------------------------------------
Contact:
Sanguine Corp., Pasadena
Thomas C. Drees, 626/405-0079
Fax: 626/405-1041 |
